Bio-Path Holdings Competitors and Similar CompaniesClear all

Bio-Path Holdings's competitors and similar companies include Vivace Therapeutics, MiracleCord, Telix Pharmaceuticals and Agenus.

	Bio-Path Holdings Bio-Path Holdings is a clinical and preclinical stage oncology focused antisense drug development company.	Vivace Therapeutics Vivace Therapeutics is a pharmaceutical company.	MiracleCord MiracleCord is a biotechnology company that provides cord blood banking services.	Telix Pharmaceuticals Telix Pharmaceuticals is a company developing molecularly targeted radiation products for cancer care.	Agenus Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer.
Founding Date	Founding Date 2007	Founding Date 2014	Founding Date 2007	Founding Date 2015	Founding Date 1994
Type	Type Public	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development medtech oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare biotech therapy	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development oncology pharma
Locations	Locations Bellaire, US HQ	Locations San Mateo, US HQ	Locations Chicago, US HQ	Locations North Melbourne, AU HQ Milton, AU Sydney, AU Herstal, BE Burnaby, CA Kyoto, JP Lancy, CH see more	Locations Lexington, US HQ Cambridge, GB Emeryville, US Berkeley, US Vacaville, US
Employees	Employees 913% increase	Employees 1122% increase	Employees 1	Employees 415	Employees 8174% decrease
Valuation ($)	Valuation ($) 4 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 4.6 b	Valuation ($) 96.2 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $803.8m (FY, 2025)	Revenue (est.) $114.2m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $356m (FY, 2025)	Cost of goods $1m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $449m (FY, 2025)	Gross profit $113.2m (FY, 2025)
Net income	Net income ($9.9m) (FY, 2024)	Net income N/A	Net income N/A	Net income ($7.1m) (FY, 2025)	Net income ($3.1m) (FY, 2025)
Funding
Latest funding round	Latest funding round N/A	Latest funding round $ 30m (over 5 years ago)	Latest funding round $ 200k (over 14 years ago)	Latest funding round N/A	Latest funding round N/A
Total funding raised	Total funding raised $ 2.3m	Total funding raised $ 70m	Total funding raised $ 200k	Total funding raised N/A	Total funding raised $ 171.1m